What’s keeping biosimilar drugs from the U.S. market?

NewsHour looks at a revolutionary class of drugs called "biologics." Americans have been paying more for their benefits than patients in Europe or Asia some say, because the "generic" versions or "biosimilars" have not hit the U.S. market. Dr. Emily Senay looks into why there's a delay and when American consumers can expect discounts.